Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib

BACKGROUND: Lenvatinib (E7080), an oral multi-kinase inhibitor, has inhibitory action on tumor cell proliferation and tumor angiogenesis in preclinical models. We evaluated correlations between pharmacodynamic (PD) biomarkers with patient clinical outcomes in a lenvatinib phase 1 dose-escalation stu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Koyama, Noriyuki, Saito, Kenichi, Nishioka, Yuki, Yusa, Wataru, Yamamoto, Noboru, Yamada, Yasuhide, Nokihara, Hiroshi, Koizumi, Fumiaki, Nishio, Kazuto, Tamura, Tomohide
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2014
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4223557/
https://ncbi.nlm.nih.gov/pubmed/25047123
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-530
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars